Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

63184

Sigma-Aldrich

5-Maleimido-eosin

for fluorescence, ≥93% (HPLC)

Synonym(s):

EMA, Eosin-5-maleimide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H9Br4NO7
CAS Number:
150322-02-4
Molecular Weight:
742.95
MDL number:
MFCD07437936
UNSPSC Code:
12352207
PubChem Substance ID:
329759808
NACRES:
NA.32

grade

for fluorescence

Quality Level

100

Assay

≥93% (HPLC)

fluorescence

λex 524 nm; λem 545 nm (after derivatization with 2-mercaptoethanol)

storage temp.

2-8°C

SMILES string

Oc1c(Br)cc2c(Oc3c(Br)c(O)c(Br)cc3C24OC(=O)c5cc(ccc45)N6C(=O)C=CC6=O)c1Br

InChI

1S/C24H9Br4NO7/c25-13-6-11-21(17(27)19(13)32)35-22-12(7-14(26)20(33)18(22)28)24(11)10-2-1-8(5-9(10)23(34)36-24)29-15(30)3-4-16(29)31/h1-7,32-33H

InChI key

YRCLWXRIEYQTAV-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

5-Maleimido-eosin, also known as EMA or Eosin-5-maleimide, is a fluorescent binding agent. The 5-Maleimido-eosin binding test measures the EMA-labeled cells reduced mean channel fluorescence (MCF) reading.

Application

Eosin-5-maleimide has been used as a fluorescent probe for the human erythrocyte band 3 protein. It is widely used as a diagnostic probe for the laboratory detection of hereditary spherocytosis (HS) by flow cytometry. The eosin-5-maleimide binding test was done to analyze the effect of alectinib (first line of treatment) for anaplastic lymphoma kinase (ALK).

Other Notes

Triplet probe. Measurement of rotational diffusion of protein in solution and in membranes, including myosin and pyruvate dehydrogenase

related product

Product No.
Description
Pricing

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCM3049
BCCL1128
BCCJ4780
BCCG9639
BCCF3538

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A J Visser et al.
European journal of biochemistry, 121(1), 233-235 (1981-12-01)
The enzymatically reduced lipoyl residues of the transacetylase component of the pyruvate dehydrogenase complex from Escherichia coli were labeled with eosin maleimide. Using eosin as triplet probe, triplet-triplet absorption dichroism measurements were performed to obtain rotational correlation times of the
S Ishiwata et al.
The Journal of biological chemistry, 262(17), 8314-8317 (1987-06-15)
We studied the rotational Brownian motions of myosin heads, of which the sulfhydryl group was selectively labeled with the triplet probe 5-eosinylmaleimide, in myofibril by using flash-induced phosphorescence anisotropy decay measurements. The anisotropy decay curve under relaxing conditions consisted of
Renée L Crisp et al.
Pediatric blood & cancer, 59(7), 1299-1301 (2012-04-11)
We studied 31 children with hemolytic anemia, or with positive family history for hereditary spherocytosis (HS), to assess the reliability of capillary blood samples for the diagnosis. HS was diagnosed in 20 patients. Cryohemolysis (CH) was positive in 94% and
Linda Hunt et al.
Cytometry. Part B, Clinical cytometry, 88(1), 50-57 (2014-09-18)
The eosin-5'-maleimide (EMA) Binding test measures reduced mean channel fluorescence (MCF) reading of EMA-labeled red cells (EMA-RBCs) from patients with hereditary spherocytosis (HS). Reporting test results can be either in the actual MCF reading or as a ratio by normalization
James A Kuzich et al.
Pathology, 53(5), 608-612 (2021-02-24)
We reviewed haematological investigations for 43 patients treated at a single centre with alectinib, an inhibitor of anaplastic lymphoma kinase (ALK) which is considered standard first-line treatment for patients with ALK-rearranged advanced non-small cell lung cancer. Ninety-five percent of patients
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service